{"id":"W4403868539","doi":"10.3389/fonc.2024.1376551","title":"First-in-human phase 1 dose-escalation results with livmoniplimab, an antibody targeting the GARP:TGF-ß1 complex, as monotherapy and in combination with the anti–PD-1 antibody budigalimab in patients with advanced solid tumors","year":2024,"lang":"en","type":"article","venue":"Frontiers in Oncology","topic":"TGF-β signaling in diseases","field":"Biochemistry, Genetics and Molecular Biology","cited_by":10,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Daiichi Sankyo Europe; Mersana Therapeutics; EMD Serono; SK Life Science; Pfizer; Merck KGaA; Genentech; Les Laboratories Pierre Fabre; Bristol-Myers Squibb; Eli Lilly and Company; AstraZeneca; Aptitude Health","keywords":"Medicine; Nausea; Combination therapy; Adverse effect; Internal medicine; Pharmacokinetics; Antibody; Pharmacology; Anemia; Monoclonal antibody; Oncology; Gastroenterology; Immunology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004991515,0.0002836195,0.0003743679,0.0002371467,0.0001483321,0.00006368501,0.0002636514,0.0001542882,0.0000029959],"category_scores_gemma":[0.00004825177,0.0001821118,0.00002528478,0.0004261522,0.0003512274,0.00004582215,0.00005645292,0.0002985034,5.120938e-7],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001498505,"about_ca_system_score_gemma":0.0001830996,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0001156128,"about_ca_topic_score_gemma":0.001095804,"domain_scores_codex":[0.9979686,0.0003127155,0.0004465213,0.0006527089,0.0002094412,0.0004100052],"domain_scores_gemma":[0.999275,0.00007340259,0.0001971127,0.000324056,0.00007303348,0.00005739174],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.01729434,0.003020182,0.9031987,0.0001151313,0.0001290072,0.0001818088,0.003689833,0.02002904,0.04444364,0.0000552793,0.0003887929,0.007454252],"study_design_scores_gemma":[0.02660413,0.009730997,0.9413812,0.0004735352,0.00004116566,0.00001255543,0.002000906,0.011261,0.004747787,0.0001605326,0.002979153,0.0006070225],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9964535,0.0007663184,0.0009903677,0.0005282093,0.0001028677,0.001003224,0.0000231474,0.0000232464,0.0001090742],"genre_scores_gemma":[0.9973853,0.0001081179,0.001278026,0.0001535924,0.00004287408,0.00008158111,0.0008860272,0.00004998137,0.00001456576],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.03969586,"threshold_uncertainty_score":0.7426304,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.007030517645121834,"score_gpt":0.3112422976780342,"score_spread":0.3042117800329123,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}